Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Fuji
Mallinckrodt
US Army
Farmers Insurance
Accenture
Healthtrust
Teva
Fish and Richardson

Generated: October 22, 2018

DrugPatentWatch Database Preview

INCRUSE ELLIPTA Drug Profile

« Back to Dashboard

Which patents cover Incruse Ellipta , and what generic alternatives are available?

Incruse Ellipta is a drug marketed by Glaxo Grp England and is included in one NDA. There are ten patents protecting this drug.

The generic ingredient in INCRUSE ELLIPTA is umeclidinium bromide. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the umeclidinium bromide profile page.

Drug patent expirations by year for INCRUSE ELLIPTA
Generic Entry Opportunity Date for INCRUSE ELLIPTA
Generic Entry Date for INCRUSE ELLIPTA *:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;INHALATION

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for INCRUSE ELLIPTA
Drug ClassAnticholinergic
Mechanism of ActionCholinergic Antagonists
Synonyms for INCRUSE ELLIPTA
1-(2-(Benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)-1-azoniabicyclo(2.2.2)octane bromide
1-(2-(benzyloxy)ethyl)-4-(hydroxydiphenylmethyl)quinuclidin-1-ium bromide
1-[2-(benzyloxy)ethyl]-4-[hydroxy(diphenyl)methyl]-1-azoniabicyclo[2.2.2]octane bromide
1-Azoniabicyclo(2.2.2)octane, 4-(hydroxydiphenylmethyl)-1-(2-(phenylmethoxy)ethyl)-, bromide (1:1)
1-Azoniabicyclo[2.2.2]octane, 4-(hydroxydiphenylmethyl)-1-[2-(phenylmethoxy)ethyl]-, bromide (1:1)
4-[Hydroxy(diphenyl)methyl]-1-{2-[(phenylmethyl)oxy]ethyl}-1-azoniabicyclo[2.2.2]octane Bromide
7AN603V4JV
869113-09-7
AK174796
AKOS025404842
bromure d'umeclidinium
bromuro de umeclidinio
CHEBI:79040
CHEMBL523299
CS-0874
D09ZOQ
D10181
diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide
DTXSID50235966
EX-A1683
GSK-573719
GSK-573719A
GSK573719A
HY-12100
Incruse ellipta (TN)
KB-81385
KS-00001CW3
MolPort-039-137-700
PEJHHXHHNGORMP-UHFFFAOYSA-M
SCHEMBL109931
umeclidinii bromidum
Umeclidinium (bromide)
Umeclidinium brom
Umeclidinium bromide
Umeclidinium bromide (JAN/USAN)
Umeclidinium bromide [USAN:INN]
Umeclidinium bromide(GSK573719A)
Umeclidinium(bromide)
UNII-7AN603V4JV
VA12030

US Patents and Regulatory Information for INCRUSE ELLIPTA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Glaxo Grp England INCRUSE ELLIPTA umeclidinium bromide POWDER;INHALATION 205382-001 Apr 30, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for INCRUSE ELLIPTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014038,C1740177 Lithuania ➤ Try a Free Trial PRODUCT NAME: UMEKLIDINO BROMIDAS; REGISTRATION NO/DATE: EU/1/14/922 20140428
90060-9 Sweden ➤ Try a Free Trial PRODUCT NAME: UMECLIDINIUM BROMIDE; REG. NO/DATE: EU/1/14/922 20140428
1740177/03 Switzerland ➤ Try a Free Trial PRODUCT NAME: UMECLIDINIUM BROMID; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Fuji
Mallinckrodt
US Army
Farmers Insurance
Accenture
Healthtrust
Teva
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.